Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 265

Similar articles for PubMed (Select 21289333)

1.

BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.

Qiu J, Compagnone M, Laibe S, Lagarde A, Goncalves A, Turrini O, Xerri L, Monges G, Olschwang S.

Cancer Genomics Proteomics. 2011 Jan-Feb;8(1):15-8.

PMID:
21289333
2.

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F.

Br J Cancer. 2009 Aug 18;101(4):715-21. doi: 10.1038/sj.bjc.6605177. Epub 2009 Jul 14.

3.

KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.

Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, Gugenheim J, Becouarn Y, Brunet R, Fonck M, François E, Saint-Paul MC, Pedeutour F.

Ann Surg Oncol. 2010 May;17(5):1429-34. doi: 10.1245/s10434-009-0864-z. Epub 2010 Jan 5.

PMID:
20049644
4.

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.

Guedes JG, Veiga I, Rocha P, Pinto P, Pinto C, Pinheiro M, Peixoto A, Fragoso M, Raimundo A, Ferreira P, Machado M, Sousa N, Lopes P, Araújo A, Macedo J, Alves F, Coutinho C, Henrique R, Santos LL, Teixeira MR.

BMC Cancer. 2013 Apr 1;13:169. doi: 10.1186/1471-2407-13-169.

5.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

6.

BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.

Mao C, Liao RY, Qiu LX, Wang XW, Ding H, Chen Q.

Mol Biol Rep. 2011 Apr;38(4):2219-23. doi: 10.1007/s11033-010-0351-4. Epub 2010 Sep 21.

PMID:
20857202
7.

BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.

Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, Pai RK.

Am J Surg Pathol. 2012 May;36(5):744-52. doi: 10.1097/PAS.0b013e31824430d7.

PMID:
22314188
8.

KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.

Pang NK, Nga ME, Chin SY, Ismail TM, Lim GL, Soong R, Salto-Tellez M.

Cytopathology. 2011 Dec;22(6):358-64. doi: 10.1111/j.1365-2303.2010.00812.x. Epub 2010 Oct 4.

PMID:
21029218
9.

Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.

Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y.

PLoS One. 2013 Dec 10;8(12):e81628. doi: 10.1371/journal.pone.0081628. eCollection 2013.

10.

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.

Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, Baldus SE, Schaefer KL.

J Cancer Res Clin Oncol. 2013 Feb;139(2):201-9. doi: 10.1007/s00432-012-1319-7. Epub 2012 Sep 27.

PMID:
23015072
11.

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M.

Clin Cancer Res. 2011 Jul 15;17(14):4901-14. doi: 10.1158/1078-0432.CCR-10-3137. Epub 2011 Jun 1.

12.

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.

Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL.

Int J Cancer. 2013 Oct 15;133(8):1914-25. doi: 10.1002/ijc.28153. Epub 2013 Jul 13. Review. Erratum in: Int J Cancer. 2014 Jul 15;135(2):E2.

PMID:
23494461
13.

Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.

Ličar A, Cerkovnik P, Novaković S.

Med Oncol. 2011 Dec;28(4):1048-53. doi: 10.1007/s12032-010-9631-z. Epub 2010 Jul 20.

PMID:
20645028
14.

Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients.

Rako I, Jakic-Razumovic J, Katalinic D, Sertic J, Plestina S.

Neoplasma. 2012;59(4):376-83. doi: 10.4149/neo_2012_049.

PMID:
22489692
15.

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. Review.

16.

KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.

Li HT, Lu YY, An YX, Wang X, Zhao QC.

Oncol Rep. 2011 Jun;25(6):1691-7. doi: 10.3892/or.2011.1217. Epub 2011 Mar 17.

PMID:
21424126
17.

PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population.

Herreros-Villanueva M, Gomez-Manero N, Muñiz P, García-Girón C, Coma del Corral MJ.

Mol Biol Rep. 2011 Feb;38(2):1347-51. doi: 10.1007/s11033-010-0236-6. Epub 2010 Jun 23.

PMID:
20571907
18.

Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.

Kakar S, Deng G, Smyrk TC, Cun L, Sahai V, Kim YS.

Mod Pathol. 2012 Jul;25(7):1040-7. doi: 10.1038/modpathol.2012.44. Epub 2012 Apr 20.

19.

Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.

Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A.

Int J Cancer. 2010 Jul 15;127(2):367-80. doi: 10.1002/ijc.25042.

PMID:
19908233
20.

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.

Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, Harris R, James MD, Meade A, Jasani B, Adams RA, Kenny S, Kaplan R, Lambrechts D, Cheadle JP.

Clin Cancer Res. 2013 Aug 1;19(15):4104-13. doi: 10.1158/1078-0432.CCR-12-2581. Epub 2013 Jun 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk